Cancer Genetics, Inc. (CGIX): Price and Financial Metrics
GET POWR RATINGS... FREE!
CGIX Stock Price Chart Interactive Chart >
CGIX Price/Volume Stats
| Current price | $4.61 | 52-week high | $17.50 |
| Prev. close | $4.72 | 52-week low | $2.11 |
| Day low | $4.30 | Volume | 612,400 |
| Day high | $4.69 | Avg. volume | 2,437,482 |
| 50-day MA | $5.46 | Dividend yield | N/A |
| 200-day MA | $3.87 | Market Cap | 18.83M |
Cancer Genetics, Inc. (CGIX) Company Bio
Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biopharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company was founded in 1999 and is based in Rutherford, New Jersey.
Latest CGIX News From Around the Web
Below are the latest news stories about Cancer Genetics Inc that investors may wish to consider to help them evaluate CGIX as an investment opportunity.
Cancer Genetics and StemoniX Announce Merger ClosingCancer Genetics, Inc. Renamed to Vyant Bio, Inc. Vyant Bio, Inc. will begin trading on Nasdaq under the symbol VYNT CHERRY HILL, N.J., March 31, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company” or “CGI”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, and StemoniX, Inc. (“StemoniX”), a company empowering the discovery of new medicines through the convergence of novel human biology and software technologies, today announced their recently approved transaction has closed, and in connection with the merger, Cancer Genetics, Inc. was renamed Vyant Bio, Inc. (“Vyant Bio”) effective March 30, 2021. StemoniX will operate as a wholly-owned subsidiary of the Company. Vyant Bio will be traded on the Nasdaq under the symbol VYNT beginning on March 31, 2021. The ... |
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniXCombined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company RUTHERFORD, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced the results of its March 24, 2021 shareholder meeting to approve the upcoming merger with StemoniX, Inc. ("StemoniX"). At a Special Meeting of Stockholders, CGI’s stockholders, upon the unanimous recommendation of the board of directors of CGI: (a) voted in favor of the issuance of shares of Common Stock, warrants and options pursuant to the Agreement and Plan of Merger and Reorganization, dated a... |
Cancer Genetics (CGIX) Investor Presentation - SlideshowThe following slide deck was published by Cancer Genetics, Inc. in conjunction with this event.... |
Cancer Genetics to Present at the Annual 33rd ROTH ConferenceRUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the Annual 33rd ROTH Conference. The event is being held virtually from March 15-17, 2021. Conference Date: March 15-17, 2021 (Monday-Wednesday)1x1 Meetings9:00 am-5:55 pm ET (Monday-Wednesday)Registration: Click Here Mr. Roberts will highlight the Company's recent transformational business strategy, including the Company’s proposed merger with StemoniX, Inc., and elaborate on the broader going- forward corporate vision. If you are an investor and would like to attend the Company’s presentation, please click on the following link (https://www.meetmax.com... |
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences ConferenceRUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at H.C. Wainwright’s Global Life Sciences Conference. The event is being held virtually from March 9-10, 2021. Conference Date: March 9-10, 2021 (Tuesday-Wednesday)On-Demand Starts: 7:00 am ET - Tuesday, March 9, 2021On-Demand Ends7:00 pm ET- Wednesday, March 10, 2021 Registration: https://hcwevents.com/globalconference/#toggle-id-1 Mr. Roberts will highlight the Company's recent transformational business strategy, including the Company’s proposed merger with StemoniX, Inc., and elaborate on the broader going- forward corporate vision. If you are an institu... |
CGIX Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -34.05% |
| 5-year | -92.85% |
| YTD | N/A |
| 2021 | 0.00% |
| 2020 | -53.52% |
| 2019 | -17.22% |
| 2018 | -87.03% |
| 2017 | 37.04% |
Continue Researching CGIX
Want to see what other sources are saying about Cancer Genetics Inc's financials and stock price? Try the links below:Cancer Genetics Inc (CGIX) Stock Price | Nasdaq
Cancer Genetics Inc (CGIX) Stock Quote, History and News - Yahoo Finance
Cancer Genetics Inc (CGIX) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...